Methods for identifying a compound that modulates activity of an iRhom polypeptide according to aspects of the present invention are described herein which include contacting a cell expressing an iRhom polypeptide with a test compound; and determining the effect of the compound on activity of the iRhom polypeptide. Detection of a decrease in proteolytic activity of the iRhom polypeptide indicates that the compound is capable of one or more of: reducing tumor growth, reducing tumor progression, treatment of cancer and promoting hair growth in a subject, and detecting an increase in proteolytic activity of the iRhom polypeptide indicates that the compound is capable of accelerating wound healing in a subject.

The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.

This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.

The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of arteriovenous fistula nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease.

The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases using trametinib and markers. The administration methods and dosage regimens induce neural regeneration and changes in gene expression.

The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.

The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.